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Abstract 
We recently demonstrated original anti-tumor effects of zoledronic acid (Zol) on 
osteosarcoma cell lines independently of their p53 and Rb status. The present study 
investigated the potential Zol-resistance acquired by osteosarcoma cells after prolonged 
treatment. After 12 weeks of culture in the presence of 1µM Zol, the effects of high doses 
of  Zol (10 to 100µM) were compared between the untreated rat (OSRGA, ROS) and 
human (MG63, SAOS2) osteosarcoma cells and Zol-pretreated cells in terms of cell 
proliferation, cell cycle analysis, migration assay and cytoskeleton organization. Long-
term treatment with 1µM Zol reduced the sensitivity of osteosarcoma cells to high 
concentrations of Zol. Furthermore, the Zol-resistant cells were sensitive to conventional 
anti-cancer agents demonstrating that this resistance process is independent of the 
multidrug resistance phenotype. However, as similar experiments performed in the 
presence of clodronate and pamidronate evidenced that this drug resistance was restricted 
to the nitrogen containing bisphosphonates, we then hypothesized that this resistance 
could be associated with a differential expression of farnesyl diphosphate synthase (FPPS) 
also observed in human osteosarcoma samples. The transfection of Zol-resistant cells with 
FPPS siRNA strongly increased their sensitivity to Zol. This study demonstrates for the 
first time the induction of metabolic resistance after prolonged Zol treatment of 
osteosarcoma cells confirming the therapeutic potential of Zol for the treatment of bone 
malignant pathologies, but points out the importance of the treatment regimen may be 
important in terms of duration and dose to avoid the development of drug metabolic 
resistance.  
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Introduction 
Osteosarcoma is the most frequent malignant primary bone tumor that develops 
mainly in the young, the median age of diagnosis being 18 years [1]. Despite recent 
improvements in chemotherapy and surgery, the problem of non-response to 
chemotherapy remains. Thus, current strategies for the treatment of high-grade 
osteosarcoma fail to improve its prognosis [2, 3], mainly because of chemotherapy 
resistance. This poor prognosis of osteosarcoma warrants new therapeutic strategies to 
improve the overall rate of survival. 
Bisphosphonates (BPs) are stable synthetic analogues deriving from endogenous 
pyrophosphate (PPi) [4]. Various side chains can be added to the central carbon atom, 
thus producing a range of BPs with differential clinical activity and potency [5]. The most 
common therapeutic application of BPs is osteoporosis, and their use has been extended 
to the treatment of malignant osteolysis and hypercalcemia. Two groups of BPs can be 
identified including non-nitrogen-containing and nitrogen-containing BPs. The BPs that 
lack a nitrogen atom, closely related to PPi (such as clodronate, etidronate and 
tiludronate) are metabolized intracellularly to cytotoxic analogues of ATP and decrease 
osteoclast survival [5]. In contrast, nitrogen-containing bisphosphonates (such as 
pamidronate, alendronate, risedronate, ibandronate and zoledronate) induce apoptosis of 
osteoclasts by inhibiting enzymes of the mevalonate pathway, especially farnesyl 
diphosphate synthase (FPPS) [6, 7] FPPS prevents the biosynthesis of cholesterol and 
isoprenoid lipids (FPP and geranylgeraniol diphosphate) which are required for the 
prenylation of small GTPases (i.e. Ras, Rho, and Rac), a biochemical reaction essential 
for the anchorage of small GTPases to cell membranes and to protein-protein interactions 
[8]. In addition to their powerful anti-bone resorption effects, recent in vitro studies 
evidenced a direct anti-tumor activity exerted by zoledronic acid (Zol) on several cancer 
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cells (myeloma, carcinoma and sarcoma) [9, 10]. Preclinical data confirmed the Zol anti-
tumor activity in experimental models of bone tumors. Among these studies, we reported 
recently the enhancement of tumor regression and tissue repair when Zol is combined 
with ifosfamide in rat osteosarcoma [11] and that Zol suppresses lung metastases and 
prolongs overall survival of osteosarcoma-bearing mice [12]. Furthermore, recent clinical 
trials in patients suffering from malignant bone diseases demonstrated that Zol was safe 
and well tolerated at the approved dose of 4 mg i.v. every 3-4 weeks [4]. Because the 
main difficulty encountered in treating cancer relates to mutations carried by many tumor 
cells in key genes such as p53, Rb or proteins affecting caspase signalling, we 
demonstrated selective and original anti-tumor effects of Zol on several osteosarcoma cell 
lines independently of their p53 and Rb status [13]. Indeed, Zol inhibited osteosarcoma 
cell proliferation through a cell cycle arrest in S and G2/M phases and induced atypical 
apoptosis independent of caspase activation, characterized by the translocation of 
Apoptosis Inducing Factor and Endonuclease-G [13]. These data now allow to consider 
these molecules as potential therapeutic agents in clinical trials of tumor bone pathologies 
independently of the p53 and Rb status of the tumor. 
 The optimization and increase in specificity of cancer treatments has improved 
their efficacy and reduced the associated adverse effects, but unfortunately has not yet 
resulted in a cure for the majority of patients. Studies of the mechanisms by which tumor 
cells escape treatment is essential to circumvent drug resistance in cancer cells and to 
design new therapeutic protocols that are not subject to these drug-resistances [14]. Two 
types of resistance mechanism have been identified [15]. The first one results in resistance 
restricted to a specific drug or limited to a small number of related drugs which can be 
bypassed by modification of the chemotherapeutic agent. The second mechanism 
confering multi-resistance to many unrelated drugs, is called  multidrug resistance (MDR) 
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and is responsible for many failures of cancer treatment [16]. The most common 
mechanisms responsible for the various forms of  resistance are the overexpression of 
efflux pumps, inhibition of apoptosis, increased repair of DNA damage, mutations in key 
cell cycle checkpoint genes and increased or altered drug targets [14]. Similar to non-
osseous malignancies, osteosarcomas frequently exhibit a MDR phenotype explaining 
why patient survival has not improved since the mid-1980s despite advances in anticancer 
therapies. Because Zol represents a potential novel anti-neoplastic agent for the therapy of 
osteosarcoma, the present study investigated the potential development of innate and/or 
acquired resistance to Zol and the molecular mechanisms involved in this phenomenon. 
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Material and Methods 
Patients 
 This study included 7 patients (3 females aged 41-93 years, 4 males aged 16-79 
years) that were referred to our institution for the treatment of osteosarcoma. All cases 
were diagnosed as osteogenic osteosarcoma based on histological samples obtained by 
open biopsies. The experimental procedures followed in the present study were in 
accordance with the ethical standards of the responsible institutional committee on human 
experimentation and with Helsinki Declaration of 1975, revised in 1983. The study was 
approved by the institutional ethic committee. 
 
Cells, culture conditions and establishment of Zol-resistant cell lines 
The rat osteosarcoma OSRGA cell line was initially established from a radio-
induced osteosarcoma [17, 18], the rat ROS17/2.8 cell line was kindly provided by Prof 
H.J. Donahue (Penn State University, USA) and the human MG63 and SAOS2 cell lines 
were purchased from ATCC (USA). These cell lines were cultured in DMEM 
(BioWhittaker, Belgium) supplemented with 5% Fetal Calf Serum (Hyclone, France) and 
2 mM L-glutamine (BioWhittaker). Rat and human osteosarcoma cell lines resistant to 
Zol (MG53res, SAOS2res, ROSres, OSRGAres) were established by 3 months of 
continuous treatment with 1µM Zol. 
 
Cell growth and viability 
Cell growth and viability were determined by a cell proliferation reagent assay kit 
using sodium 3’[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-
nitro)benzene sulfonic acid hydrate (XTT) (Roche Molecular Biomedicals, Germany). 
Two thousand cells/well were plated into 96-well plates and cultured for 72h in culture 
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medium in the presence or the absence of 10-12 to 10-4 M Zol. Zol was provided by 
Novartis Pharma AG (Switzerland) as the disodium hydrate form. In another set of 
experiments, cells were treated for 72 h in the presence or the absence of 10-9 to 10-6 M 
methotrexate (Sigma, France), doxorubicine (Sigma) and 1 to 50 µg/ml mafosfamide 
(Baxter, France), 10 to 1000 µM clodronate (Sigma), 1 to 500 µM pamidronate (Sigma) 
and 5µM verapamil (Sigma). After the culture period, XTT reagent was added to each 
well and incubated for 5h at 37°C, the corresponding absorbance was then determined at 
490 nm. Cell viability was also assessed by trypan blue exclusion and live and dead cells 
were scored manually. Cell death was also monitored microscopically after Hoechst 
n°33258 staining (Sigma). In this experiment, cells were seeded at 104 cells/well in a 24-
well plate and treated or not with 10 µM Zol for 48 hours or 100 nM staurosporine 
(Sigma) for 16 hours, stained by 10 µg/ml Hoechst reagent for  30 min at 37°C and then 
observed under UV microscopy (DMRXA, Leica, Germany).  
 
Western blot analysis 
Zol-treated cells were lysed in RIPA buffer (150 mM NaCl, 5% Tris pH 7.4, 1% 
NP-40, 0.25% Na deoxycholate, 1 mM Na3VO4, 0.5 mM PMSF, 10 µg/ml leupeptin, 10 
µg/ml aprotinin). Protein concentration was determined by the BCA kit (Pierce Chemical, 
USA). Fifty µg of total cell lysate protein were run on SDS-PAGE, electrophoretically 
transferred to Immobilon-P membrane (Millipore, MA, USA). The membrane was blotted 
with antibodies anti-p-Rb (Ser 807/811), -p-cdc2 (tyr15), -actin (Cell Signaling 
Technologies, USA), -p21WAF1(BD Biosciences USA) and the unprenylated form of 
Rap1A (Santa Cruz, USA) to indirectly quantified FPPS enzymatic activity, in PBS, 
0.05% Tween 20, and 3% bovine serum albumin (BSA). The membrane was washed and 
probed with the secondary antibody coupled to horseradish peroxidase. Antibody binding 
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was then visualized with the enhanced chemoluminescence system (ECL Kit; Roche 
Molecular Biomedicals). The band densities were measured using the GeneTools 
computer software program (SynGene). 
Caspase -1, -3 and -8 activities 
Caspase -1, -3 and -8 activities were assessed on 10 µl of total Zol-treated or not 
cell lysates using the kit CaspACETM Assay System, “Fluorometric” (Promega, USA) 
following the manufacturer’s recommendations. Cells treated with UV light for 30 
seconds 24 h before harvesting were used as a positive control. Results were expressed in 
arbitrary units referred to the total protein content. 
 
Cell cycle analysis 
OSRGA, MG63 and SAOS2 cells were incubated in the absence or the presence of 
10 µM Zol for 48 hours, trypsinized, washed twice and incubated in PBS containing 
0.12% Triton X-100, 0.12 mM EDTA and 100 µg/ml ribonuclease A. Then 50 µg/ml 
propidium iodide were added to each sample for 20 min at 4°C. Cell cycle distribution 
was analyzed by flow cytometry (FAC Scan), based on 2N and 4N DNA content. 
 
Time-lapse microscopy and confocal microscopic analysis 
For time-lapse experiments, cells were seeded at 5 x 104 cells/well and cultured in 
6-multiwell plates in the absence or the presence of 10 µM Zol. Phase-contrast 
photographs (Leica) were taken every 10 min during 60 h and edited using the 
MetamorphTM software. Cell divisions and apoptotic cells were then manually scored. To 
study cell migration, cells plated in 6-well plates and cultured until confluence were 
treated or not with 10 µM Zol for 24 h before a slit was made in the cell monolayer. Actin 
filament detection was performed after cell treatment with or without 10 µM Zol fixed in 
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4% paraformaldehyde and stained with FITC-conjugated phalloidin (0.25 µg/ml; Sigma). 
Cover glasses were fitted with the Long Pro Kit (Molecular probes). Images were 
collected on a Leica TCS-SP1 confocal microscope with 63/1.4x oil immersion lens. The 
digital images were visualized with a 24-bit imaging system including Leica’s TCS-NT 
software and projections were generated from z-stacks. 
 
siRNA gene silencer 
The FPPS gene expression was knocked down using specific human and rat FPPS 
siRNA (Ambion, France) and the INTERFERinTM  transfection reagent (Polyplus 
transfection, France). Cells were seeded at 40% confluency in a 24-well plate one day 
before transfection. In each well 10 nM siRNA duplexes diluted in serum-free medium 
were incubated with 2 µl of INTERFERinTM for 30 min at room temperature. Then, 100 
µl mixture per well were added onto the cells and incubated at 37°C. The 72h-Zol 
treatment started 24 h after siRNA transfection. For each condition tested, a negative 
siRNA control was used (Santa Cruz biotechnology, Germany). Additional experiments 
were performed in the presence of geranylgeraniol (GGO) (Sigma, France).  
 
 
RT-PCR analysis  
Total RNA was isolated from cultured OSRGA, MG63 and SAOS2 cells using the 
TRIzol reagent (Invitrogen, France). First, RNA was reversed-transcribed (RT), using 400 
U MMLV-RT from Invitrogen, then 2 µl of the RT reaction mixture were subjected to 
PCR using upstream and downstream primers to determine the expression of rat and 
human FPPS [Human FPPS sense: AGATCTGTGGGGGTCTTCCT, anti sense: 
TCCCGGAATGCTACTACCAC; Rat FPPS sense: AGTACAATCGGGGTCTGACG, 
anti sense: CGCGATAGGCAGGTAGAAAG] and 0.25 µl of 5 U/µl Taq polymerase 
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(Eurobio, France). After the number of PCR cycles was increased, a plot was done for 
each sample, the cycle values corresponding to the linear part of the amplification curve 
were then determined (28 cycles, Tm=58°C) and used to quantify the message versus the 
18S signal determined in the same way. The PCR products were electrophoresed in 1% 
agarose gel containing ethidium bromide. The band densities were measured using the 
GeneTools computer software program. Three independent experiments were performed 
for each gene and a representative experiment is shown in the Results section. 
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Results 
Osteosarcoma cell lines develop Zol-resistance after long-term continuous treatment 
with low dose Zol 
 Consistent with previous results [11, 12, 19], Zol treatment of Zol-sensitive rat 
ROS, OSRGA(Figure 1A) and human MG63, SAOS2 (Figure 1B) osteosarcoma cells 
strongly reduced their proliferation. Thus, 0.1 to 100 µM Zol decreased the viable cell 
number in a dose-dependent manner (IC50: 1 to 8 µM) as revealed by the XTT assay. 
After 3 month continuous treatment with 1 µM Zol, rat and human osteosarcoma cells 
became less sensitive to Zol and resistant cell lines (OSRGAres, ROSres, MG63res, 
SAOS2res) were then progressively established (Figure 1A). Indeed, the potency of Zol to 
affect cell proliferation was strongly reduced on human resistant cell lines and Zol was 
ineffective on rat resistant cell lines (Figures 1A).  
 The influence of this resistance process was also assessed on the other known 
activities of Zol on tumor cells [cell cycle (Figure 1B), DNA checkpoints (Figure 1B), 
cytoskeleton (Figure 1C), cell migration (Figure 1C) [13]].  Cell cycle analysis was 
performed after 48h of 10 µM Zol-treatment. The results obtained confirmed that 48h of 
Zol-treatment induced a strong cell cycle arrest in S and G2/M phases in Zol-sensitive 
OSRGA cells (Figure 1B, [13]) and showed that Zol-treatment did not modulate the cell 
cycle in OSRGAres cells (Figure 1B). Indeed, the number of cells in S, G2/M phases 
strongly increased from 35% to 53% for OSRGA cells in the presence of 10 µM Zol 
concomitantly with a decrease of cells in G0/G1 phase: 42% vs. 64%  (Figure 1B). A 
similar phenomenon was observed in human osteosarcoma cell lines (data not shown). 
We therefore investigated by western blot whether the DNA checkpoint proteins were 
involved in the cell cycle blockade observed in the presence of Zol. Thus, the treatment of 
sensitive OSRGA cells by 10 µM Zol increased the inactive form of cdc2 (p-cdc2, Tyr15) 
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after 72 hours of treatment. Simultaneously, Zol strongly reduced p21 expression and 
transiently upregulated Rb phosphorylation (Ser 807 and 811) after 24h of Zol treatment 
(Figure 1B). No modulation of p-cdc2, Rb and p21 was observed in OSRGAres cells 
regardless of the duration of Zol treatment (Figure 1B).  
As Zol has been shown to disturb cytoskeletal organization and to inhibit cell 
migration [13], we wondered whether Zol could alter such parameters in OSRGAres cells. 
Confocal microscopy revealed a major disorganization of the actin stress fibres associated 
with membrane ruffling in sensitive OSRGA cells treated with 10 µM Zol for 72 h, this 
was never observed in OSRGAres cells (Figure 1C). Moreover, as shown by the time-
lapse assay, 10 µM Zol totally blocked the migration of sensitive OSRGA cells but was 
not able to abolish migration of OSRGAres cells (Figure 1C). 
 .  
 
The molecular mechanism involved in the reduced-Zol sensitivity is not associated 
with a multidrug resistance (MDR) phenotype and is restricted to the nitrogen-
containing bisphosphonates 
The potential role of the MDR phenotype in the Zol resistance phenomenon was 
assessed by XTT assays. The MDR phenotype is conventionally defined as the resistance 
of cells to conventional chemotherapeutic agents such as mafosfamide, methotrexate and 
doxorubicin [20, 21]. The XTT assays revealed that OSRGAres cells were still always 
sensitive to increasing doses of mafosfamide, methotrexate, and doxorubicin (Figure 2). 
Furthermore, 5µM verapamil, a P-gp pump inhibitor [22] was not able to abolish the Zol 
resistance (Figure 2). Overall, these data demonstrate that the Zol resistance was not 
associated with MDR phenotype. In addition, similar experiments performed in the 
presence of clodronate, a non-nitrogen containing-BP [4], revealed that OSRGAres are as 
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sensitive  to clodronate as they are to lower concentrations of Zol (Figure 2). When, 
osteosarcoma cells were treated with another nitrogen-containing BP, pamidronate which 
also targets FPPS, it significantly reduced Zol-sensitive OSRGA proliferation in contrast 
to OSRGAres cells which are also resistant to pamidronate (Figure 2). Similar results 
have been obtained with the osteosarcoma cell lines MG63 and SAOS2 (data not shown). 
These experiments demonstrated that the Zol-resistance phenomenon in osteosarcoma 
cells appears to be MDR-independent and is apparently restricted to nitrogen-containing 
BPs.  
 
Farnesyl diphosphate synthase (FPPS) is implicated in the Zol-resistance mechanism 
of osteosarcoma cell lines 
FPPS being the main molecular target of nitrogen containing BPs [23], the FPPS 
transcript expression was analyzed by RT-PCR and compared in sensitive OSRGA and 
OSRGAres cells (Figure 1D). Thus, the Zol resistant cells expressed a higher level of FPPS 
mRNA than the sensitive cells. To further determine the involvement of FPPS in the Zol-
resistance mechanism of human and rat osteosarcoma cells, the effect of Zol on OSRGA, 
OSRGAres, MG63 and SAOS2 was analyzed after transfection with FPPS siRNA. Semi-
quantitative RT-PCR analysis was used to evaluate the efficacy of FPPS siRNA on FPPS 
mRNA expression. In all experiments, FPPS mRNA levels were significantly decreased in 
FPPS siRNA transfected cell lines compared to the siRNA control (Figure 3A). Inhibition of 
FPPS activity was then assessed indirectly by the expression of the unprenylated form of the 
small GTPase Rap1A (unRAP1A) that is expressed after inhibition of FPPS [24, 25] (Figure 
3B). The transfection of Zol-sensitive cells with FPPS siRNA strongly increased their 
sensitivity to Zol in all osteosarcoma cell lines studied. Indeed, FPPS siRNA transfection 
modified the unRAP1A expression kinetic in OSRGA, MG63 and SAOS2 cells. In the 
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presence of FPPS siRNA, unRAP1A expression was strongly induced by 1µM Zol treatment 
for 24h whereas its expression was only observed with 10 µM Zol treatment for 48h in 
control siRNA transfected cells (Figure 3B). In OSRGAres cells, a very weak expression of 
unRAP1A was observed after Zol treatment. Interestingly, FPPS siRNA re-induced the 
sentivity to Zol treatment in these resistant cells to a level comparable to parental OSRGA 
cells transfected with FPPS siRNA.  Thus, the unRAP1A expression was observed after 24h 
treatment with 1µM Zol in FPPS siRNA-OSRGAres transfected (Figure 3B). Similarly, 
micoscopic observations confirmed the FPPS siRNA effects on the sensitization of 
osteosarcoma cells to Zol treatment (Figure 3C). Thus, an increase of floating cell number 
associated with an inhibition of cell proliferation was observed after transfection of all 
osteosarcoma cell lines with FPPS siRNA (Figure 3C).  
XTT analyses were performed to determine the impact of FPPS siRNA on Zol 
activity (Figure 3D). Transfection with FPPS siRNA significantly increased the sensitivity 
to Zol treatment of all osteosarcoma cell lines analyzed (Figure 3D). The sensitivity to 
10µM Zol was up-modulated by 22%, 31%, 53% and 42% in OSRGA, OSRGAres MG63 
and SAOS2 respectively in the presence of FPPS siRNA compared to the control siRNA 
(Figure 3D). Furthermore, the efficacy of FPPS siRNA occured for lower doses of Zol in 
OSRGAres compared to OSRGA cells (respectively 22% and 1% increase of sensitivity 
in the presence of 0.1 µM Zol) (Figure 3D).   
 
siRNA FPPS increases the Zol-induced blockade of the cell cycle in S, G2/M phases 
in osteosarcoma cell lines 
We previously demonstrated that Zol induces osteosarcoma cell cycle arrest in S, 
G2/M phases in OSRGA sensitive cells [13]. To determine whether FPPS siRNA could 
modulate this sensitivity, the cell cycle of FPPS siRNA transfected osteosarcoma cells 
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was analyzed by flow cytometry. Figure 4 reveals that FPPS siRNA accentuates the Zol-
induced effects observed on cell cycle distribution, leading to a significant increase of 
cells blocked in S phase compared to the control siRNA.  Indeed, the number of cells in S 
phase increased from 26% to 30% for OSRGA, from 20% to 26% for MG63, from 34% 
to 46% for SAOS2 and from 23% to 38% for OSRGAres cells in the presence of FPPS 
siRNA compared to the control siRNA after 48h of treatment with 10 µM Zol (Figure 4). 
Furthermore, these observations were concomitant with a significant reduction of the cell 
number in G0/G1 phase: 35% vs. 42% for OSRGA, 61% vs. 69% for MG63, 36% vs. 57% 
for SAOS2 and 41% vs 53% for OSRGAres.  
 
Geranyl geraniol (GGO) reversed the FPPS siRNA effects in osteosarcoma cell lines 
 To determine whether the effects previously demonstrated for the FPPS siRNA in 
osteosarcoma cells are reversible, FPPS siRNA transfected cells treated with increasing 
doses of Zol were cultured in the presence of 25µM geranylgeraniol, the FPPS metabolic 
product (Figure 5). GGO protected rat and human osteosarcoma cell lines from the effects 
of Zol in the FFPS siRNA transfected cells and totally reversed FPPS siRNA effects 
(Figure 5A). We therefore investigated by western blot the expression kinetic of 
unRAP1A in the presence of 25µM GGO in FPPS siRNA transfected cells (Figure 5B). 
GGO totally abolished unRAP1A expression similar to what had been observed in Zol-
resistant cell lines (Figure 3B). Overall, these data then strengthen our conclusion that 
FPPS is involved in the Zol-resistance mechanism. 
 
Dual origin of Zol resistance: innate and/or acquired  
 To explain the origin of the Zol-resistance observed in osteosarcoma cell lines, 
two hypotheses can be proposed: (i) an innate resistance mechanism linked to differential 
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levels of FPPS expression and associated with selection of a sub-population of cells 
expressing a higher FPPS activity, (ii) an acquired resistance mechanism linked to an 
increased FPPS transcription level as a feedback response to long-term, low dose Zol 
treatment. To distinguish between these two hypotheses, OSRGA osteosarcoma cell lines 
were treated with low Zol concentrations (1 pM to 104 pM) for 72 h (Figure 6A). Low 
concentrations of Zol induced a 60% increase of viable cells and up-modulated the 
expression of FPPS mRNA in a dose dependent manner (Figure 6A), these results support 
acquired resistance to Zol. Since a potential mechanism of innate resistance could be also 
envisaged, OSRGA cell line was cloned by limiting dilution and the expression of FPPS 
was analyzed by semi-quantitative RT-PCR (Figure 6B). Several clones were isolated 
with heterogenous sensitivity to Zol treatment (Figure 6B). Furthermore, the isolated 
clones expressed differential levels of FPPS related to their sensitivity to Zol treatment, 
these results support innate resistance to Zol (Figure 6B). Similarly, we analyzed the 
transcriptional expression of FFPS in 7 human osteosarcoma samples analyzed by semi-
quantitative RT-PCR before any chemotherapy (Figure 6C). The results revealed that a 
very high heterogeneity of FPPS expression in these patients strengthening the hypothesis 
of innate resistance to Zol.  
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Discussion 
 The first effects of bisphosphonates on calcium metabolism were discovered over 
30 years ago, and these drugs have become the most widely used agents in the treatment 
of bone diseases associated with excessive resorption (osteoporosis, malignant osteolysis, 
etc). The recent evidences of an anti-tumor effect of nitrogen-containing BPs has led to 
investigation of the potential acquired resistance mechanism. Indeed, failure of anti-
cancer therapies often occur from innate or acquired drug resistance of the tumor cells to 
the chemotherapeutic agents [26]. In this context, the elucidation of potential resistance 
mechanisms to the zoledronic acid (Zol) will allow adaptation of the treatment regimen in 
terms of duration and dose to avoid the development of drug resistance. The present study 
demonstrated that after 3 months of continuous treatment with 1µM Zol, osteosarcoma 
cell lines became less sensitive to Zol inhibition and resistant cell lines were then 
progressively established. Furthermore, this resistance appeared to be independent of the 
MDR phenotype and was clearly related to a differential expression of farnesyl 
diphosphate synthase (FPPS). 
 To exert its activities, Zol must be internalized by cells. Although the mode of Zol 
internalization is still controversial, two mechanisms have been proposed: first, cellular 
uptake of Zol may require fluid-phase endocytosis in osteoclasts [27]; in the second case, 
integrins located at the cell membrane could represent a binding site for Zol which could 
explain why Zol is able to inhibit cell adhesion and that RGD peptide prevents the Zol 
effects on osteosarcoma cell lines [13]. However, it remains unclear whether cell types 
other than osteoclasts can internalize BPs [27]. Recently, Notarnicola et al demonstrated 
that high FPPS activity level correlates to a stronger inhibition of cellular apoptosis in 
colorectal cancer cells [28]. Similarly, Ortiz-Gomez et al demonstrated that 
overexpression of FPPS confers resistance to risedronate in Leishmania major and that 
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the degree of resistance was correlated with an increase in this enzymatic activity [29]. 
These data strongly support our present results and strengthen the pivotal function of 
FPPS in the Zol-resistance mechanism. Athough FPPS is considered as the main target of 
nitrogen containing-BPs, the inhibition of prenylation being the most likely explanation 
for their biological effects, van Beek et al evidenced that undetermined additional 
mechanisms could be involved which may be also proposed for specific resistance 
mechanisms in certain specific cell types [30].  
 In the present study, we wondered what could be the origin of the Zol-induced 
resistance mechanism: an innate or an acquired resistance mechanism? In fact, the results 
did not allow us to distinguish between these two hypotheses. The main argument in favor 
of an innate resistance mechanism is the differential FPPS expression of OSRGA 
osteosarcoma sub-clones composing the heterogenous “parental” OSRGA cell line. 
Indeed, Zol treatment exerts a selective inhibitory effect on cancer cells expressing less 
FPPS and after several weeks of culture, FPPS overexpressing cells become predominant 
and emerge from the parental population (Figure 6B)[28]. On the other hand, the effect of 
Zol treatment on FPPS expression is in favor of an acquired resistance mechanism. 
Indeed, 72h treatment with low doses of Zol (1 to 104pM) increased FPPS expression in 
OSRGA cells (Figure 6A) inducing the development of FPPS overexpressing tumor cells 
(Figure 1D). Similar involvement has been envisaged in myloma cells [31]. This 
hypothesis was also strengthened by Ortiz-Gomez et al who obtained resistant cell lines 
by stepwise selection in the presence of risedronate, resulting in the development of 
resistant promastigotes exhibiting increased levels of FPPS at the transcriptional and the 
translational levels [29]. These authors considered that as a result of drug pressure, cells 
overcame the effects of risedronate by overexpressing the target protein. Such 
modification has been already observed in osteosarcoma patients treated with 
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chemotherapy. Indeed, after comparison of primary biopsy tissue with that removed after 
metastasectomy, genetic changes acquired by the tumors have been demonstrated [32, 
33]. An acquired resistance to bisphosphonates was also reported by Papapoulos et al in 
Paget’s disease [34]. These authors argued that resistance to the action of bisphosphonates 
in Paget’s disease is caused by disease-related factors rather than decreased 
responsiveness of the molecular target in contrast to the present data. They supported this 
hypothesis with studies using statins that target the same intracellular biochemical 
pathway upstream of FPPS, these studies showed no evidence of development of 
resistance to their action [35, 36]. They also presented data suggesting that acquired 
resistance is specific for pamidronate and does not extend to other nitrogen-containing 
BPs. In summary, various and concomitant resistance mechanisms can not be excluded: 
direct or indirect effects on FPPS, innate and/or acquired mechanisms.    
 Chemotherapy resistance in osteosarcoma is well documented [37]. Osteosarcoma 
cells are subjected to genetic disturbances such as alterations in the tumor suppressor 
pathways centered on p53 and Rb [38, 39], changes in oncogenes / anti-oncogenes such as 
deletions in p16INK4A (cyclin-dependent kinase inhibitor 2A), c-fos overexpression and 
amplification of cyclin-dependent kinase 4 [40-42]. These genetics instabilities lead to 
heterogenic cell populations within the same tumor and to the emergence of resistant 
tumor cells. The most described resistance phenomena concern widely used 
chemotherapeutic agents such as cisplatin, doxorubicin or methotrexate. In these cases, 
the resistance mechanisms involved are: mutation of the drug target, up- or down-
regulation of the drug target, decreased drug uptake, drug inactivation, increased drug 
elimination and increased DNA repair [43-45]. Multidrug resistance phenotype (MDR), 
due to P-gp or related protein overexpression is the most reported resistance mechanism.  
In osteosarcoma, MDR1 [46] or P-gp [47] expression could be used as a prognostic 
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marker for sensitivity to chemotherapy, allowing the selection of patients for whom 
alternative treatments may be considered. Recently, other prognostic factors have been 
described, such as the expression level of clusterin/apolipoprotein J [48] or expression of 
a pregnane xenobiotic receptor (PXR) a major inducer of cytochrome P450 3A4 [49]. 
Therefore, these factors may also represent predictive markers correlating with the 
response of cancer cells to chemotherapy.  
 We described in ostesarcoma a Zol-resistance mechanism specific to nitrogen-
containing BPs which did not confer simultaneous resistance to other unrelated drugs. In 
this context, drug resistance could be circumvented using multiple drugs with different 
cellular targets and different mechanisms of action. For instance, when Zol is associated 
with ifosfamide in rat osteosarcoma, enhanced tumor regression and tissue repair have 
been observed [11]. In the future, Zol could be combined with other chemotherapeutic 
agent to increase therapeutic efficacy and avoid the emergence of resistance mechanism 
[50].  
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Figure legends 
Figure 1: Osteosarcoma cell lines develop Zol-resistance after long-term of 
continuous treatment with low doses of Zol 
 A: rat (OSRGA, ROS) and  human (MG63, SAOS2) sensitive and resistant 
(corresponding cell Name-res) osteosarcoma cell lines were treated with increasing 
concentrations of Zol (0.1 µM to 100 µM) for 72 h. The number of viable cells was then 
measured using the XTT assay. Graphs represent the mean values of three independent 
experiments performed in triplicate.  
B: Cell cycle distribution of OSRGA and OSRGAres, treated or not with 10 µM Zol for 
48 h were analyzed by propidium iodide staining and FACS analysis. G1/S and G2/M 
DNA checkpoints were analyzed by western blot and compared between sensitive and 
resistant OSRGA osteosarcoma cell lines in the presence or absence of 10 µM Zol for 24, 
48 and 72 h. All experiments were repeated 3 times and a representative blot is shown. 
C: Zol effects on organization of actin stress fibres were observed by confocal 
microscopy after phalloïdine staining. The actin network reorganization was associated 
with membrane ruffling (white arrow) in Zol-sensitive OSRGA cell line (Original 
magnification: x1000). Zol effects on cell migration were also analyzed by time lapse 
microscopy. The horizontal bars represent the limit of the slit cut performed on the cell 
monolayer at the start of the experiment (Original magnification: x100). 
D: Farnesyl diphosphate synthase (FPPS) transcription level was determined by semi 
quantitative RT-PCR in OSRGA sensitive and resistant cell lines. 18S was used as a 
control. 
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Figure 2: The molecular mechanism involved in the reduced-Zol sensitivity is not 
associated with a multidrug resistance (MDR) phenotype and is restricted to the 
nitrogen-containing bisphosphonates 
OSRGA and OSRGAres sensitivity to conventional anti-cancer agents mafosfamide,  
methotrexate, doxorubicin and sensitivity to Zol in the presence or absence of a P-gp 
pump inhibitor (5µM verapamil) was analyzed by the XTT assay. Similar experiments 
were performed in the presence of clodronate and pamidronate. Graphs represent the 
mean values of three independent experiments performed in triplicate. Error bars 
represent the standard deviation. 
 
Figure 3: Involvement of farnesyl diphosphate synthase (FPPS) in the Zol-induced 
resistance mechanism in osteosarcoma 
A: Farnesyl diphosphate synthase (FPPS) transcription level was determined by semi 
quantitative RT-PCR in FPPS siRNA transfected cell lines compared to the siRNA 
control cells. 18S was used as a control.  
B: Western blot analysis of unprenylated RAP1A (unRAP1A) from OSRGA cell lines 
transfected with FPPS siRNA and control siRNA, treated 24 and 48h with 1 and 10 µM 
Zol  All experiments were repeated 3 times, and a representative blot is shown. 
C: Photomicrographs of FPPS siRNA transfected cells after 48 h with 10 µM Zol 
compared to control siRNA. Original magnification: x100. 
D: Rat (OSRGA, OSRGAres) and human (MG63, SAOS2) osteosarcoma cell lines were 
transfected with FPPS siRNA and treated after 24h of culture by increasing 
concentrations of Zol (0.1 µM to 10 µM) for 72 h. The number of viable cells was then 
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determined using the XTT assay. Histograms represent the percentage of the increased 
sensitivity to Zol in the presence of FPPS siRNA compared to control siRNA. Values are 
mean of three independent experiments performed in triplicate. Error bars represent the 
standard deviation. 
 
Figure 4: FPPS siRNA increases the Zol-induced blockade of the cell cycle in S 
phases in osteosarcoma cell lines 
Cell cycle distribution of osteosarcoma cell lines (FPPS siRNA vs control siRNA) treated 
or not with 10 µM Zol for 48 h were analyzed by propidium iodide staining and FACS 
analysis. 
 
Figure 5: Geranylgeraniol (GGO) reverses FPPS siRNA effects in osteosarcoma cell 
lines 
A: Rat (OSRGA) and human (MG63, SAOS2) osteosarcoma cell lines were transfected 
with FPPS siRNA and treated 24h after with increasing concentrations of Zol (0.1 µM to 
100 µM) for 72 h in the presence or not of 25 µM GGO. The number of viable cells was 
then determined using the XTT assay. Graphs represent the mean values of three 
independent experiments performed in triplicate. Error bars represent the standard 
deviation. 
B: Western blot analysis of unprenylated RAP1A (unRAP1A) form. Cells transfected 
with control siRNA or with FPPS siRNA combined with 25 µM GGO were treated with 1 
and 10µM Zol for 24 and 48 h. All experiments were repeated 3 times, and a 
representative blot is shown. 
 
Figure 6: Dual origin of Zol-resistance: innate and/or acquired 
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A: OSRGA osteosarcoma cell lines were treated with increasing low concentration of Zol 
(1 pM to 104 pM) for 72 h. The number of viable cells was then determined using a XTT 
assay. Graphs represent the average values of three independent experiments performed in 
triplicate. Error bars represent the standard deviation. Farnesyl diphosphate synthase 
(FPPS) transcription level was determined by semi-quantitative RT PCR under the same 
conditions of Zol treatment. 18S was used as a control. 
B: Similar experiments were performed with higher concentrations of Zol (0.1 µM to 100 
µM) in two OSRGA clones obtained by limiting dilution. 
C: Transcriptional analysis of FFPS in 7 human osteosarcoma samples analyzed by semi-
quantitative RT-PCR  
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